Latest News

STAT Plus: IBM halting sales of Watson AI tool for drug discovery amid sluggish growth

Citing lackluster financial performance, IBM is halting development and sales of a product that uses its Watson artificial intelligence software to help pharmaceutical companies discover new drugs, according to a person familiar with the company’s internal decision-making.

The decision to shut down sales of Watson for Drug Discovery marks the highest-profile retreat in the company’s effort to apply artificial intelligence to various areas of health care. Last year, the company scaled back on the hospital side of its business, and it’s struggled to develop a reliable tool to assist doctors in treating cancer patients.

Continue to STAT Plus to read the full story…

Source link

Related posts

The North American Pharmaceutical Contract Packaging Market: 2019-2024 Analysis and Forecast –


BD Unveils Nano Pen Needle for Accurate Subcutaneous Insulin Injections


Medical News Today: What to know about paranoid personality disorder


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy